Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus Rituximab in R/R DLBCL, FL, and MZL
NCT03520920Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jan 2018
- Primary completion
- Aug 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL) (2 arms), sponsored by BeiGene. Primary endpoint: Overall Response Rate at 2.5 years. Started Jan 2018; status: completed.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03520920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520920.